医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

SUWON, South Korea

OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company’s management will participate in one-on-one partnering meetings at the 2022 BIO International Convention, being held in-person from June 13 to 16, 2022.

Dong Ki Lee, Ph.D., Founder and Chief Executive Officer, and June Park, Ph.D., Head of R&D at OliX Pharmaceuticals, will meet global industry experts to discuss platform-based early discovery collaborations as well as global licensing options for the Company’s pipeline programs.

The main treatment programs of OliX include OLX101A for hypertrophic scars which the Company has recently completed patient enrollment for, OLX104C for androgenic alopecia (hair loss), OLX301A for dry and wet age-related macular degeneration (AMD), OLX702A for nonalcoholic steatohepatitis (NASH), and OLX703A for hepatitis B virus (HBV).

To schedule a meeting, please visit the 2022 BIO International Convention here.

About OliX Pharmaceuticals

OliX Pharmaceuticals is a clinical-stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating the expression of disease-causing genes based on its own proprietary RNAi technology. The Company’s core RNAi platform, asymmetric siRNA (asiRNA), is a unique gene silencing technology based on RNA interference (RNAi), which is considered the most efficient gene silencing technology. Utilizing this proprietary asiRNA technology, OliX has developed cell penetrating asiRNA (cp-asiRNA), a therapeutic RNAi platform to effectively target diseases locally, such as hypertrophic scarring, dry and wet age-related macular degeneration (AMD), subretinal fibrosis, and neuropathic pain. OliX has also developed another therapeutic RNAi platform, GalNAc-asiRNA, to target a variety of liver diseases.

Learn more: https://www.olixpharma.com/eng

View source version on businesswire.com: https://www.businesswire.com/news/home/20220609005413/en/